secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zentalis Pharmaceuticals, Inc. (ZNTL)
CIK:        0001725160
Form:       8-K
Filed at:   2023-06-15T23:59:59+00:00
Accession:  0001725160-23-000137
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Zentalis regains global rights to azenosertib, ZN-d5, ZN-c5 from Zentera
------------------------------------------------------------------------

- Terminated collaboration with Zentera Therapeutics; now holds worldwide development/commercialization rights to three drug candidates.
- Pays $30M upfront, milestone payment, and low single-digit royalty on Greater China net sales of azenosertib, ZN-d5, ZN-c5.
- Sold its 40.3% equity stake in Zentera back to Zentera for de minimis consideration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000137/0001725160-23-000137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725160/000172516023000137/zntl-20230615.htm
  HTML page:      https://secwatch.observer/filing/0001725160-23-000137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer